DDInter38 DDInter298
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Vinblastine
Vinblastine {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Vinblastine
Vinblastine {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Betamethasone {u} (Compound) palliates {v} (Disease) brain cancer
brain cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Aldesleukin may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) palliates brain cancer (Disease) and brain cancer (Disease) is treated by Carboplatin (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)